low
Sell
150,000 shares
$8,159,277
Significance
4/10
Christopher Hite sells 150,000 shares (21.1% reduction) for $8,159,276.82 via scheduled 10b5-1 plan
Christopher Hite, who was then EVP & Chairman, Partnering at Royalty Pharma, executed two separate sales totaling 150,000 shares (150.0K shares) for $8,159,276.82 on 2026-06-23 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-20. The sales reduced his holdings from 709,399 shares to 559,399 shares, representing a -21.1% reduction in his position. As a scheduled transaction under Rule 10b5-1, this sale was not discretionary and therefore does not reflect current decision-making about the stock's direction or his conviction level at the time of filing.